Literature DB >> 10417771

Soluble MUC1 secreted by human epithelial cancer cells mediates immune suppression by blocking T-cell activation.

A K Chan1, D C Lockhart, W von Bernstorff, R A Spanjaard, H G Joo, T J Eberlein, P S Goedegebuure.   

Abstract

Solid tumors may secrete factors that mediate immune suppression in patients. We investigated the effect of supernatants from 25 human tumor cell lines on T-lymphocytes from healthy donors. A profound inhibition of proliferation, cytokine secretion and cytotoxic activity was seen when T-cells were cultured in concentrated tumor supernatants from 6 cell lines fractionated into high (>100 kDa) m.w. molecules. Interestingly, the inhibitory effects were reversed when the tumor supernatant was removed. Cell cycle studies of inhibited T-cells showed most of them were growth arrested in the G(0)/G(1) phase similar to naïve T-cells. In addition, these T-cells did not express IL2-receptors and expression of CD54 (ICAM-1) and CD58 (LFA-3) resembled that of resting T-cells. Protein gel electrophoresis of the tumor supernatants and western blot analysis demonstrated the presence of soluble MUC1 in the inhibitory tumor supernatants but not in control supernatant. Most importantly, depletion of soluble MUC1 by immunoprecipitation from the tumor supernatants neutralized the inhibitory effects on T-lymphocytes. Therefore, our results show that MUC1 shed by cultured epithelial tumor cells mediates inhibition of T-cell proliferation and function by inducing cell growth arrest. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10417771     DOI: 10.1002/(sici)1097-0215(19990827)82:5<721::aid-ijc16>3.0.co;2-n

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  19 in total

1.  Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration.

Authors:  Isabel Correa; Tim Plunkett; Anda Vlad; Arron Mungul; Jessica Candelora-Kettel; Joy M Burchell; Joyce Taylor-Papadimitriou; Olivera J Finn
Journal:  Immunology       Date:  2003-01       Impact factor: 7.397

2.  Aptamer–biotin–streptavidin–C1q complexes can trigger the classical complement pathway to kill cancer cells.

Authors:  John Gordon Bruno
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-02       Impact factor: 2.416

3.  MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form.

Authors:  R L ten Berge; F G Snijdewint; S von Mensdorff-Pouilly; R J Poort-Keesom; J J Oudejans; J W Meijer; R Willemze; J Hilgers; C J Meijer
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

4.  Significance of Proline Residue on Short Mucin Peptide Interactions with Mouse MUC1 Monoclonal Antibody Studied by Saturation Transfer Difference NMR Spectroscopy.

Authors:  Cheng Her; William M Westler; Thao Yang
Journal:  JSM Chem       Date:  2013-10-17

5.  Breast cancer and protein biomarkers.

Authors:  Lay-Harn Gam
Journal:  World J Exp Med       Date:  2012-10-20

6.  Dynamics and visualization of MCF7 adenocarcinoma cell death by aptamer-C1q-mediated membrane attack.

Authors:  John R Stecker; Alissa A Savage; John G Bruno; Dana M García; Joseph R Koke
Journal:  Nucleic Acid Ther       Date:  2012-08-03       Impact factor: 5.486

7.  MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma.

Authors:  Teresa L Tinder; Durai B Subramani; Gargi D Basu; Judy M Bradley; Jorge Schettini; Arefayene Million; Todd Skaar; Pinku Mukherjee
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

8.  MUC1 inhibits cell proliferation by a beta-catenin-dependent mechanism.

Authors:  Erik P Lillehoj; Wenju Lu; Timothy Kiser; Simeon E Goldblum; K Chul Kim
Journal:  Biochim Biophys Acta       Date:  2007-04-22

9.  Antigenic differences between metastatic cells in bone marrow and primary tumours and the anti-MUC1 humoral immune response induced in breast cancer patients.

Authors:  M V Croce; M Isla-Larrain; R Tur; M E Rabassa; A Segal-Eiras
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

10.  Characterization of Cell-Bound CA125 on Immune Cell Subtypes of Ovarian Cancer Patients Using a Novel Imaging Platform.

Authors:  Germán González; Kornél Lakatos; Jawad Hoballah; Roberta Fritz-Klaus; Lojain Al-Johani; Jeff Brooker; Sinyoung Jeong; Conor L Evans; Petra Krauledat; Daniel W Cramer; Robert A Hoffman; W Peter Hansen; Manish S Patankar
Journal:  Cancers (Basel)       Date:  2021-04-25       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.